JP2008540637A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540637A5 JP2008540637A5 JP2008511823A JP2008511823A JP2008540637A5 JP 2008540637 A5 JP2008540637 A5 JP 2008540637A5 JP 2008511823 A JP2008511823 A JP 2008511823A JP 2008511823 A JP2008511823 A JP 2008511823A JP 2008540637 A5 JP2008540637 A5 JP 2008540637A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methanone
- oxadiazol
- fluoro
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 112
- 125000003118 aryl group Chemical group 0.000 claims 69
- 125000001072 heteroaryl group Chemical group 0.000 claims 57
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 48
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 33
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 33
- 125000003710 aryl alkyl group Chemical group 0.000 claims 27
- 229910052736 halogen Inorganic materials 0.000 claims 27
- 150000002367 halogens Chemical class 0.000 claims 27
- 125000001424 substituent group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 125000002877 alkyl aryl group Chemical group 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 14
- -1 hydroxy, Amino Chemical group 0.000 claims 13
- 208000015114 central nervous system disease Diseases 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 150000001204 N-oxides Chemical class 0.000 claims 7
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 7
- 125000004103 aminoalkyl group Chemical group 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 7
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 201000000980 schizophrenia Diseases 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 3
- 208000019899 phobic disease Diseases 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010010305 Confusional state Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 208000029650 alcohol withdrawal Diseases 0.000 claims 2
- 230000003281 allosteric effect Effects 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000003227 neuromodulating effect Effects 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- KSXKNDXBIXELCD-NSHDSACASA-N (2-fluoropyridin-4-yl)-[(3S)-3-[3-(4-fluoro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound FC1=CNC(C=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=C(F)N=CC=2)=C1 KSXKNDXBIXELCD-NSHDSACASA-N 0.000 claims 1
- IKIBDZSIUXXBPN-ZDUSSCGKSA-N (2-fluoropyridin-4-yl)-[(3S)-3-[3-(4-methyl-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound CC1=CNC(C=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=C(F)N=CC=2)=C1 IKIBDZSIUXXBPN-ZDUSSCGKSA-N 0.000 claims 1
- QLBRRGDJRUMOKT-NSHDSACASA-N (2-fluoropyridin-4-yl)-[(3S)-3-[5-(4-fluoro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound FC1=CNC(C=2ON=C(N=2)[C@@H]2CN(CCC2)C(=O)C=2C=C(F)N=CC=2)=C1 QLBRRGDJRUMOKT-NSHDSACASA-N 0.000 claims 1
- AEFNJYKVPGWFAJ-ZDUSSCGKSA-N (2-fluoropyridin-4-yl)-[(3S)-3-[5-(4-methyl-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound CC1=CNC(C=2ON=C(N=2)[C@@H]2CN(CCC2)C(=O)C=2C=C(F)N=CC=2)=C1 AEFNJYKVPGWFAJ-ZDUSSCGKSA-N 0.000 claims 1
- SEYRJKFTKMQBRG-NSHDSACASA-N (3,4-difluorophenyl)-[(3S)-3-[3-(1H-imidazol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(N=2)C=2NC=CN=2)CCC1 SEYRJKFTKMQBRG-NSHDSACASA-N 0.000 claims 1
- MXKYYIGEZKOXLE-NSHDSACASA-N (3,4-difluorophenyl)-[(3S)-3-[3-(4-fluoro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound FC1=CNC(C=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=C(F)C(F)=CC=2)=C1 MXKYYIGEZKOXLE-NSHDSACASA-N 0.000 claims 1
- YJCUKJKFBXZCNP-ZDUSSCGKSA-N (3,4-difluorophenyl)-[(3S)-3-[3-(4-methyl-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound CC1=CNC(C=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=C(F)C(F)=CC=2)=C1 YJCUKJKFBXZCNP-ZDUSSCGKSA-N 0.000 claims 1
- RANDMAUZUPLZBV-LBPRGKRZSA-N (3,4-difluorophenyl)-[(3S)-3-[3-(5-methyl-1H-imidazol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound CC1=CNC(C=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=C(F)C(F)=CC=2)=N1 RANDMAUZUPLZBV-LBPRGKRZSA-N 0.000 claims 1
- NYWQJTBZFYWELR-UHFFFAOYSA-N (3,4-difluorophenyl)-[3-[5-(1H-imidazol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2NC=CN=2)CCC1 NYWQJTBZFYWELR-UHFFFAOYSA-N 0.000 claims 1
- ZKBIQSQAINHYDH-JTQLQIEISA-N (3-fluoropyridin-4-yl)-[(3S)-3-[3-(4-fluoro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound FC1=CNC(C=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C(=CN=CC=2)F)=C1 ZKBIQSQAINHYDH-JTQLQIEISA-N 0.000 claims 1
- GYLZIHOGODNVFM-LBPRGKRZSA-N (3-fluoropyridin-4-yl)-[(3S)-3-[3-(4-methyl-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound CC1=CNC(C=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C(=CN=CC=2)F)=C1 GYLZIHOGODNVFM-LBPRGKRZSA-N 0.000 claims 1
- BRCRDKHUCOPYIX-JTQLQIEISA-N (3-fluoropyridin-4-yl)-[(3S)-3-[5-(4-fluoro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound FC1=CNC(C=2ON=C(N=2)[C@@H]2CN(CCC2)C(=O)C=2C(=CN=CC=2)F)=C1 BRCRDKHUCOPYIX-JTQLQIEISA-N 0.000 claims 1
- FDXZZEJGKWWZJF-LBPRGKRZSA-N (3-fluoropyridin-4-yl)-[(3S)-3-[5-(4-methyl-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound CC1=CNC(C=2ON=C(N=2)[C@@H]2CN(CCC2)C(=O)C=2C(=CN=CC=2)F)=C1 FDXZZEJGKWWZJF-LBPRGKRZSA-N 0.000 claims 1
- BWUIIXZUPYXCHA-UHFFFAOYSA-N (4-fluoro-2-methylphenyl)-[3-[5-(1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound CC1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2NC=CC=2)CCC1 BWUIIXZUPYXCHA-UHFFFAOYSA-N 0.000 claims 1
- BOYOGJRLPORQHQ-CYBMUJFWSA-N (4-fluorophenyl)-[(3R)-3-[3-(1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@H](C=2ON=C(N=2)C=2NC=CC=2)CCC1 BOYOGJRLPORQHQ-CYBMUJFWSA-N 0.000 claims 1
- ZVBWKKUICJBUMA-LBPRGKRZSA-N (4-fluorophenyl)-[(3S)-3-[3-(1H-imidazol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(N=2)C=2NC=CN=2)CCC1 ZVBWKKUICJBUMA-LBPRGKRZSA-N 0.000 claims 1
- SQMDCGNVPLTEKC-INIZCTEOSA-N (4-fluorophenyl)-[(3S)-3-[3-(1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(N=2)C=2NC3=CC=CC=C3C=2)CCC1 SQMDCGNVPLTEKC-INIZCTEOSA-N 0.000 claims 1
- BOYOGJRLPORQHQ-ZDUSSCGKSA-N (4-fluorophenyl)-[(3S)-3-[3-(1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(N=2)C=2NC=CC=2)CCC1 BOYOGJRLPORQHQ-ZDUSSCGKSA-N 0.000 claims 1
- HJXCSGVDVREFMF-LBPRGKRZSA-N (4-fluorophenyl)-[(3S)-3-[3-(4-fluoro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound FC1=CNC(C=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=CC(F)=CC=2)=C1 HJXCSGVDVREFMF-LBPRGKRZSA-N 0.000 claims 1
- HLVWOWMABVMDJF-AWEZNQCLSA-N (4-fluorophenyl)-[(3S)-3-[3-(4-methyl-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound CC1=CNC(C=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=CC(F)=CC=2)=C1 HLVWOWMABVMDJF-AWEZNQCLSA-N 0.000 claims 1
- CASDWRSPIJRATR-ZDUSSCGKSA-N (4-fluorophenyl)-[(3S)-3-[5-(1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2NC=CC=2)CCC1 CASDWRSPIJRATR-ZDUSSCGKSA-N 0.000 claims 1
- PEJDLTDYANPRBU-AWEZNQCLSA-N (4-fluorophenyl)-[(3S)-3-[5-(1H-pyrrol-2-yl)tetrazol-2-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](N2N=C(N=N2)C=2NC=CC=2)CCC1 PEJDLTDYANPRBU-AWEZNQCLSA-N 0.000 claims 1
- FRJFUXJSUQQNCU-AWEZNQCLSA-N (4-fluorophenyl)-[(3S)-3-[5-(4-methyl-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound CC1=CNC(C=2ON=C(N=2)[C@@H]2CN(CCC2)C(=O)C=2C=CC(F)=CC=2)=C1 FRJFUXJSUQQNCU-AWEZNQCLSA-N 0.000 claims 1
- YXDHTPMKZWXQJY-LBPRGKRZSA-N (4-fluorophenyl)-[(3S)-3-[5-(4-nitro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound [O-][N+](=O)C1=CNC(C=2ON=C(N=2)[C@@H]2CN(CCC2)C(=O)C=2C=CC(F)=CC=2)=C1 YXDHTPMKZWXQJY-LBPRGKRZSA-N 0.000 claims 1
- OPJOCZBZZGEFQF-AWEZNQCLSA-N (4-fluorophenyl)-[(3S)-3-[5-(5-methyl-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound N1C(C)=CC=C1C1=NC([C@@H]2CN(CCC2)C(=O)C=2C=CC(F)=CC=2)=NO1 OPJOCZBZZGEFQF-AWEZNQCLSA-N 0.000 claims 1
- MPWGXODNRIEULU-LBPRGKRZSA-N (4-fluorophenyl)-[(3S)-3-[5-[4-(trifluoromethyl)-1H-pyrrol-2-yl]-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2NC=C(C=2)C(F)(F)F)CCC1 MPWGXODNRIEULU-LBPRGKRZSA-N 0.000 claims 1
- LEYCRBLXWJCRJH-NSHDSACASA-N (4-fluorophenyl)-[(3S)-3-[5-[5-(trifluoromethyl)-1H-imidazol-2-yl]-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2NC=C(N=2)C(F)(F)F)CCC1 LEYCRBLXWJCRJH-NSHDSACASA-N 0.000 claims 1
- BOACXNJMYAYPHQ-UHFFFAOYSA-N (4-fluorophenyl)-[3-[3-(1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]pyrrolidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(C=2ON=C(N=2)C=2NC=CC=2)CC1 BOACXNJMYAYPHQ-UHFFFAOYSA-N 0.000 claims 1
- UURXMBRSMGNNJJ-UHFFFAOYSA-N (4-fluorophenyl)-[3-[5-(1H-imidazol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2NC=CN=2)CCC1 UURXMBRSMGNNJJ-UHFFFAOYSA-N 0.000 claims 1
- FGFLALOXMGHYSF-UHFFFAOYSA-N (4-fluorophenyl)-[3-[5-(1H-indol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2NC3=CC=CC=C3C=2)CCC1 FGFLALOXMGHYSF-UHFFFAOYSA-N 0.000 claims 1
- DLYJIYVTYRDZRK-UHFFFAOYSA-N (4-fluorophenyl)-[3-fluoro-3-[3-(1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(F)(C=2ON=C(N=2)C=2NC=CC=2)CCC1 DLYJIYVTYRDZRK-UHFFFAOYSA-N 0.000 claims 1
- UKVAXKVWSLHODI-NSHDSACASA-N (5-methyl-1,2-oxazol-4-yl)-[(3S)-3-[3-(1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound O1N=CC(C(=O)N2C[C@H](CCC2)C=2ON=C(N=2)C=2NC=CC=2)=C1C UKVAXKVWSLHODI-NSHDSACASA-N 0.000 claims 1
- RIYADNUXTBLENX-LBPRGKRZSA-N (6-fluoropyridin-3-yl)-[(3S)-3-[3-(1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(N=2)C=2NC=CC=2)CCC1 RIYADNUXTBLENX-LBPRGKRZSA-N 0.000 claims 1
- KIIWYGFIAGRWCK-NSHDSACASA-N (6-fluoropyridin-3-yl)-[(3S)-3-[3-(4-fluoro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone Chemical compound FC1=CNC(C=2N=C(ON=2)[C@@H]2CN(CCC2)C(=O)C=2C=NC(F)=CC=2)=C1 KIIWYGFIAGRWCK-NSHDSACASA-N 0.000 claims 1
- NPNMZYZWXVIMHP-LBPRGKRZSA-N (6-fluoropyridin-3-yl)-[(3S)-3-[5-(1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2NC=CC=2)CCC1 NPNMZYZWXVIMHP-LBPRGKRZSA-N 0.000 claims 1
- NDDJGMXSCVMBQD-NSHDSACASA-N (6-fluoropyridin-3-yl)-[(3S)-3-[5-(4-fluoro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound FC1=CNC(C=2ON=C(N=2)[C@@H]2CN(CCC2)C(=O)C=2C=NC(F)=CC=2)=C1 NDDJGMXSCVMBQD-NSHDSACASA-N 0.000 claims 1
- JNQJYRKKMMRSEN-ZDUSSCGKSA-N (6-fluoropyridin-3-yl)-[(3S)-3-[5-(4-methyl-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound CC1=CNC(C=2ON=C(N=2)[C@@H]2CN(CCC2)C(=O)C=2C=NC(F)=CC=2)=C1 JNQJYRKKMMRSEN-ZDUSSCGKSA-N 0.000 claims 1
- OJYIYJOUIBEIFY-AWEZNQCLSA-N (6-fluoropyridin-3-yl)-[(3S)-3-[5-(4-propan-2-yl-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound CC(C)C1=CNC(C=2ON=C(N=2)[C@@H]2CN(CCC2)C(=O)C=2C=NC(F)=CC=2)=C1 OJYIYJOUIBEIFY-AWEZNQCLSA-N 0.000 claims 1
- KMOVFCHENLIRBU-UHFFFAOYSA-N (6-fluoropyridin-3-yl)-[3-[5-(1H-indol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1CC(C=2N=C(ON=2)C=2NC3=CC=CC=C3C=2)CCC1 KMOVFCHENLIRBU-UHFFFAOYSA-N 0.000 claims 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- OCPSZCLVPMDVKZ-AWEZNQCLSA-N 5-[3-[(3S)-1-(4-fluorobenzoyl)piperidin-3-yl]-1,2,4-oxadiazol-5-yl]-1H-pyrrole-3-carbonitrile Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2NC=C(C=2)C#N)CCC1 OCPSZCLVPMDVKZ-AWEZNQCLSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- KHNUTPQQWKDHRA-UHFFFAOYSA-N FC=1C=C(C=CC1F)C(=O)N1CC(CCC1)C1=NOC(=N1)C=1NN=CC1.FC1=CC=C(C=C1)C(=O)N1CC(CCC1)C1=NOC(=N1)C=1NN=CC1 Chemical compound FC=1C=C(C=CC1F)C(=O)N1CC(CCC1)C1=NOC(=N1)C=1NN=CC1.FC1=CC=C(C=C1)C(=O)N1CC(CCC1)C1=NOC(=N1)C=1NN=CC1 KHNUTPQQWKDHRA-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- VHUKCDQQGOZAKI-AWEZNQCLSA-N [(3S)-3-[3-(1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(5-methyl-1,2-oxazol-4-yl)methanone Chemical compound O1N=CC(C(=O)N2C[C@H](CCC2)C=2ON=C(N=2)C=2NC3=CC=CC=C3C=2)=C1C VHUKCDQQGOZAKI-AWEZNQCLSA-N 0.000 claims 1
- FQNJQIVIFMDQFU-JTQLQIEISA-N [(3S)-3-[3-(4-bromo-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(3-fluoropyridin-4-yl)methanone Chemical compound FC1=CN=CC=C1C(=O)N1C[C@@H](C=2ON=C(N=2)C=2NC=C(Br)C=2)CCC1 FQNJQIVIFMDQFU-JTQLQIEISA-N 0.000 claims 1
- WJGIFYOYAZPULZ-LBPRGKRZSA-N [(3S)-3-[3-(4-bromo-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(N=2)C=2NC=C(Br)C=2)CCC1 WJGIFYOYAZPULZ-LBPRGKRZSA-N 0.000 claims 1
- QVXOZSLTORWKSR-NSHDSACASA-N [(3S)-3-[3-(4-bromo-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(6-fluoropyridin-3-yl)methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(N=2)C=2NC=C(Br)C=2)CCC1 QVXOZSLTORWKSR-NSHDSACASA-N 0.000 claims 1
- DHPFMOYDVDUNHK-JTQLQIEISA-N [(3S)-3-[3-(4-chloro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(3-fluoropyridin-4-yl)methanone Chemical compound FC1=CN=CC=C1C(=O)N1C[C@@H](C=2ON=C(N=2)C=2NC=C(Cl)C=2)CCC1 DHPFMOYDVDUNHK-JTQLQIEISA-N 0.000 claims 1
- CVXSESIHZWEERI-LBPRGKRZSA-N [(3S)-3-[3-(4-chloro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(N=2)C=2NC=C(Cl)C=2)CCC1 CVXSESIHZWEERI-LBPRGKRZSA-N 0.000 claims 1
- NVSAVHVPXFTLOY-JTQLQIEISA-N [(3S)-3-[3-(4-chloro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(5-methyl-1,2-oxazol-4-yl)methanone Chemical compound O1N=CC(C(=O)N2C[C@H](CCC2)C=2ON=C(N=2)C=2NC=C(Cl)C=2)=C1C NVSAVHVPXFTLOY-JTQLQIEISA-N 0.000 claims 1
- QNECFJNGNJLPGW-NSHDSACASA-N [(3S)-3-[3-(4-chloro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(6-fluoropyridin-3-yl)methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1C[C@@H](C=2ON=C(N=2)C=2NC=C(Cl)C=2)CCC1 QNECFJNGNJLPGW-NSHDSACASA-N 0.000 claims 1
- WHGRYTYIQIILBL-JTQLQIEISA-N [(3S)-3-[5-(4-bromo-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(3-fluoropyridin-4-yl)methanone Chemical compound FC1=CN=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2NC=C(Br)C=2)CCC1 WHGRYTYIQIILBL-JTQLQIEISA-N 0.000 claims 1
- AWUZMJOSTMJVGT-NSHDSACASA-N [(3S)-3-[5-(4-bromo-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(6-fluoropyridin-3-yl)methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2NC=C(Br)C=2)CCC1 AWUZMJOSTMJVGT-NSHDSACASA-N 0.000 claims 1
- COMUOENAGNUWHL-NSHDSACASA-N [(3S)-3-[5-(4-chloro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(2-fluoropyridin-4-yl)methanone Chemical compound C1=NC(F)=CC(C(=O)N2C[C@H](CCC2)C=2N=C(ON=2)C=2NC=C(Cl)C=2)=C1 COMUOENAGNUWHL-NSHDSACASA-N 0.000 claims 1
- ABRKSVQEXBIEIL-JTQLQIEISA-N [(3S)-3-[5-(4-chloro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(3-fluoropyridin-4-yl)methanone Chemical compound FC1=CN=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2NC=C(Cl)C=2)CCC1 ABRKSVQEXBIEIL-JTQLQIEISA-N 0.000 claims 1
- FUZQYPIJFKDVBA-LBPRGKRZSA-N [(3S)-3-[5-(4-chloro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2NC=C(Cl)C=2)CCC1 FUZQYPIJFKDVBA-LBPRGKRZSA-N 0.000 claims 1
- XPHFSSTZTFJTPH-JTQLQIEISA-N [(3S)-3-[5-(4-chloro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(5-methyl-1,2-oxazol-4-yl)methanone Chemical compound O1N=CC(C(=O)N2C[C@H](CCC2)C=2N=C(ON=2)C=2NC=C(Cl)C=2)=C1C XPHFSSTZTFJTPH-JTQLQIEISA-N 0.000 claims 1
- DPCQYPIHDBOVBS-NSHDSACASA-N [(3S)-3-[5-(4-chloro-1H-pyrrol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(6-fluoropyridin-3-yl)methanone Chemical compound C1=NC(F)=CC=C1C(=O)N1C[C@@H](C=2N=C(ON=2)C=2NC=C(Cl)C=2)CCC1 DPCQYPIHDBOVBS-NSHDSACASA-N 0.000 claims 1
- OQAPHKQVICSYCZ-UHFFFAOYSA-N [3,3-difluoro-5-[3-(1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(F)(F)CC(C=2ON=C(N=2)C=2NC=CC=2)C1 OQAPHKQVICSYCZ-UHFFFAOYSA-N 0.000 claims 1
- XVAABGNNUKIUAY-UHFFFAOYSA-N [3,3-dimethyl-5-[3-(1H-pyrrol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1C(C)(C)CC(C=2ON=C(N=2)C=2NC=CC=2)CN1C(=O)C1=CC=C(F)C=C1 XVAABGNNUKIUAY-UHFFFAOYSA-N 0.000 claims 1
- QXKOTZWHZBKENM-UHFFFAOYSA-N [3-[5-(1H-indol-2-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-(5-methyl-1,2-oxazol-4-yl)methanone Chemical compound O1N=CC(C(=O)N2CC(CCC2)C=2N=C(ON=2)C=2NC3=CC=CC=C3C=2)=C1C QXKOTZWHZBKENM-UHFFFAOYSA-N 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 239000000700 radioactive tracer Substances 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 201000006137 substance-induced psychosis Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 0 Cc1c(*)c(*)c(*)[n]1 Chemical compound Cc1c(*)c(*)c(*)[n]1 0.000 description 18
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0510141.5A GB0510141D0 (en) | 2005-05-18 | 2005-05-18 | Novel compounds B3 |
| PCT/IB2006/002047 WO2006123257A2 (en) | 2005-05-18 | 2006-05-17 | Phenyl-3-{(3-(1h-pyrrol-2-yl)-[1, 2 , 4]0xadiaz0l-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012118718A Division JP2012184254A (ja) | 2005-05-18 | 2012-05-24 | 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540637A JP2008540637A (ja) | 2008-11-20 |
| JP2008540637A5 true JP2008540637A5 (enExample) | 2009-06-18 |
Family
ID=34708379
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511823A Pending JP2008540637A (ja) | 2005-05-18 | 2006-05-17 | 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体 |
| JP2012118718A Withdrawn JP2012184254A (ja) | 2005-05-18 | 2012-05-24 | 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012118718A Withdrawn JP2012184254A (ja) | 2005-05-18 | 2012-05-24 | 陽性の代謝型グルタミン酸受容体アロステリックモジュレーターとしてのピロール誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090203737A1 (enExample) |
| EP (1) | EP1912979B1 (enExample) |
| JP (2) | JP2008540637A (enExample) |
| KR (1) | KR20080014046A (enExample) |
| CN (1) | CN101218234B (enExample) |
| AT (1) | ATE513828T1 (enExample) |
| AU (1) | AU2006248657B2 (enExample) |
| BR (1) | BRPI0610059A2 (enExample) |
| CA (1) | CA2608324A1 (enExample) |
| CY (1) | CY1111859T1 (enExample) |
| DK (1) | DK1912979T3 (enExample) |
| EA (1) | EA014081B1 (enExample) |
| ES (1) | ES2367663T3 (enExample) |
| GB (1) | GB0510141D0 (enExample) |
| IL (1) | IL187187A0 (enExample) |
| MX (1) | MX2007014403A (enExample) |
| NO (1) | NO20076480L (enExample) |
| NZ (1) | NZ564202A (enExample) |
| PL (1) | PL1912979T3 (enExample) |
| PT (1) | PT1912979E (enExample) |
| UA (1) | UA92494C2 (enExample) |
| WO (1) | WO2006123257A2 (enExample) |
| ZA (1) | ZA200710279B (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| CA2608014A1 (en) * | 2005-05-18 | 2006-11-23 | Addex Pharma Sa | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510140D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| GB0622202D0 (en) * | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
| CA2696016A1 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| EP2197873B1 (en) | 2007-09-20 | 2014-07-16 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| WO2010089119A1 (en) * | 2009-02-04 | 2010-08-12 | Recordati Ireland Limited | Heterocyclic derivatives as m-glu5 antagonists |
| TW201035088A (en) | 2009-02-27 | 2010-10-01 | Supergen Inc | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
| US20120040998A1 (en) * | 2009-04-23 | 2012-02-16 | Mercer Swati P | 2-alkyl piperidine mglur5 receptor modulators |
| GB0912946D0 (en) | 2009-07-24 | 2009-09-02 | Addex Pharmaceuticals Sa | New compounds 5 |
| CA2784830C (en) | 2009-12-18 | 2018-03-27 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| US8835444B2 (en) | 2010-02-02 | 2014-09-16 | Novartis Ag | Cyclohexyl amide derivatives as CRF receptor antagonists |
| EP3159331A1 (en) | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| CN105130967B (zh) | 2011-05-13 | 2018-04-17 | 阵列生物制药公司 | 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物 |
| SG2014011555A (en) | 2011-08-15 | 2014-08-28 | Intermune Inc | Lysophosphatidic acid receptor antagonists |
| KR101699822B1 (ko) | 2011-12-21 | 2017-01-25 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| AR092269A1 (es) | 2012-08-28 | 2015-04-08 | Janssen R&D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| MX365733B (es) | 2012-11-13 | 2019-06-12 | Array Biopharma Inc | Compuestos de n-pirrolidinil, n' -pirazolil-urea, tiourea, guanidina y cianoguanidina como inhibidores de trka cinasa. |
| US9790210B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078372A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
| RU2664541C2 (ru) | 2012-11-13 | 2018-08-20 | Эррэй Биофарма Инк. | Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли |
| US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| SI2961732T1 (sl) | 2013-02-28 | 2017-07-31 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| SG10201805033XA (en) | 2013-07-25 | 2018-07-30 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| JP6452119B2 (ja) | 2013-10-23 | 2019-01-16 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用 |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| JP6553059B2 (ja) | 2014-02-05 | 2019-07-31 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｈｂｖ感染の治療のための併用療法 |
| US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| HUE045340T2 (hu) | 2014-05-15 | 2019-12-30 | Array Biopharma Inc | 1-((3S,4R)-4-(3-fluorfenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2- metilpirimidin-5-il)-1-fenil-1H-pirazol-5-il)karbamid mint TrkA kináz inhibitor |
| CA2980298A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| CN108430971A (zh) | 2015-09-29 | 2018-08-21 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| BR112018071048A2 (pt) | 2016-04-15 | 2019-05-07 | Janssen Sciences Ireland Uc | combinações e métodos que compreendem um inibidor da montagem de capsídeos |
| CN111712494A (zh) | 2018-02-13 | 2020-09-25 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| BR112020018601A2 (pt) | 2018-03-14 | 2020-12-29 | Janssen Sciences Ireland Unlimited Company | Regime de dosagem de modulador de montagem de capsídeo |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US20220089581A1 (en) * | 2019-01-25 | 2022-03-24 | University Of Virginia Patent Foundation | Inhibitors of spinster homolog 2 (spns2) for use in therapy |
| AU2020223865A1 (en) | 2019-02-22 | 2021-07-15 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| TW202108576A (zh) | 2019-05-06 | 2021-03-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之醯胺衍生物 |
| HUE069128T2 (hu) | 2019-12-06 | 2025-02-28 | Vertex Pharma | Szubsztituált tetrahidrofurán vegyületek mint nátriumcsatornák modulátorai |
| AU2020417293A1 (en) | 2020-01-03 | 2022-09-01 | Berg Llc | Polycyclic amides as UBE2K modulators for treating cancer |
| WO2022069953A1 (en) * | 2020-09-29 | 2022-04-07 | Ranjith Siddaraj | Synthesis and characterization of (s)-3-(5- fluoropyridin-2-yl)-5-(piperidin-3-yl)-l,2,4-oxadiazole derivatives and their secretory phospholipase a2 (spla2) inhibitor activity |
| AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| WO2024059207A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | Pyrazoloether analogs as mglu5 negative allosteric modulators and methods of making and using the same |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3509153A (en) * | 1967-03-24 | 1970-04-28 | Miles Lab | 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles |
| US3991064A (en) * | 1975-01-17 | 1976-11-09 | Warner-Lambert Company | Benzonaphthyridines |
| US3966748A (en) * | 1975-05-08 | 1976-06-29 | American Cyanamid Company | Para-fluorophenyl-N-heterocyclic substituted butanes |
| US5338969A (en) * | 1991-06-27 | 1994-08-16 | Texas Instruments, Incorporated | Unerasable programmable read-only memory |
| US6846839B1 (en) * | 1995-06-07 | 2005-01-25 | Sugen, Inc. | Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis |
| GB9603755D0 (en) * | 1996-02-22 | 1996-04-24 | Pfizer Ltd | Therapeutic agents |
| US6437146B1 (en) * | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| US7217714B1 (en) * | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
| WO2000066578A1 (en) * | 1999-04-30 | 2000-11-09 | Pfizer Products Inc. | Compounds for the treatment of obesity |
| PL356485A1 (en) * | 1999-12-16 | 2004-06-28 | Schering Corporation | Substituted imidazole neuropeptide y y5 receptor antagonists |
| AR033517A1 (es) * | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| KR100904011B1 (ko) * | 2000-06-12 | 2009-06-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 1,2-디하이드로피리딘 화합물 및 그의 제조 방법 |
| WO2001096302A1 (en) * | 2000-06-16 | 2001-12-20 | Smithkline Beecham P.L.C. | Piperidines for use as orexin receptor antagonists |
| US6894063B2 (en) * | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
| US6946476B2 (en) * | 2000-12-21 | 2005-09-20 | Schering Corporation | Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
| SI1427720T1 (sl) * | 2001-09-21 | 2009-08-31 | Mitsubishi Tanabe Pharma Corp | 3-substituirani-4-pirimidonski derivati |
| TWI303171B (en) * | 2001-09-21 | 2008-11-21 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| ATE396186T1 (de) * | 2001-10-04 | 2008-06-15 | Merck & Co Inc | Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 |
| US20050014942A1 (en) * | 2001-10-30 | 2005-01-20 | Yasufumi Maruyama | Amide derivatives and drugs |
| US6806279B2 (en) * | 2001-12-17 | 2004-10-19 | Sunesis Pharmaceuticals, Inc. | Small-molecule inhibitors of interleukin-2 |
| AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| WO2003093236A1 (en) * | 2002-05-02 | 2003-11-13 | Euro-Celtique, S.A. | 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor |
| CA2484209C (en) * | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| EP1581525A2 (en) * | 2002-08-09 | 2005-10-05 | AstraZeneca AB | Compounds having an activity at metabotropic glutamate receptors |
| US20040127501A1 (en) * | 2002-09-24 | 2004-07-01 | Zhengming Chen | Therapeutic agents useful for treating pain |
| KR100875318B1 (ko) * | 2002-11-26 | 2008-12-22 | 화이자 프로덕츠 인크. | Ｐｐａｒ 활성화 인자로 사용하기 위한 페닐 치환된피페리딘 화합물 |
| US7582635B2 (en) * | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| ES2327684T3 (es) * | 2003-07-24 | 2009-11-02 | Euro-Celtique S.A. | Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor. |
| JP4769721B2 (ja) * | 2003-08-25 | 2011-09-07 | トロヴィス ファーマシューティカルズ リミテッド ライアビリティ カンパニー | 置換８−ヘテロアリールキサンチン |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| FR2865733B1 (fr) * | 2004-02-04 | 2007-10-12 | Merck Sante Sas | Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine |
| EP1753426A2 (en) * | 2004-05-25 | 2007-02-21 | Pfizer Products Incorporated | Ruminant treatments |
| DE602005026546D1 (de) * | 2004-09-29 | 2011-04-07 | Mitsubishi Tanabe Pharma Corp | Der tau-proteinkinase-1 |
| WO2006044509A2 (en) * | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
| GB0510143D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| WO2006048771A1 (en) * | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| US7713998B2 (en) * | 2004-11-10 | 2010-05-11 | Ono Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic compound and pharmaceutical use thereof |
| WO2006065601A2 (en) * | 2004-12-15 | 2006-06-22 | Merck & Co., Inc. | Inhibitors of akt activity |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| GB0510140D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
| CA2608014A1 (en) * | 2005-05-18 | 2006-11-23 | Addex Pharma Sa | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| GB0622202D0 (en) * | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
-
2005
- 2005-05-18 GB GBGB0510141.5A patent/GB0510141D0/en not_active Ceased
-
2006
- 2006-05-17 AU AU2006248657A patent/AU2006248657B2/en not_active Expired - Fee Related
- 2006-05-17 PL PL06779899T patent/PL1912979T3/pl unknown
- 2006-05-17 JP JP2008511823A patent/JP2008540637A/ja active Pending
- 2006-05-17 UA UAA200714061A patent/UA92494C2/ru unknown
- 2006-05-17 KR KR1020077029429A patent/KR20080014046A/ko not_active Ceased
- 2006-05-17 MX MX2007014403A patent/MX2007014403A/es active IP Right Grant
- 2006-05-17 DK DK06779899.1T patent/DK1912979T3/da active
- 2006-05-17 EA EA200702470A patent/EA014081B1/ru not_active IP Right Cessation
- 2006-05-17 AT AT06779899T patent/ATE513828T1/de active
- 2006-05-17 CN CN2006800251802A patent/CN101218234B/zh not_active Expired - Fee Related
- 2006-05-17 BR BRPI0610059-7A patent/BRPI0610059A2/pt not_active IP Right Cessation
- 2006-05-17 NZ NZ564202A patent/NZ564202A/en not_active IP Right Cessation
- 2006-05-17 US US11/920,490 patent/US20090203737A1/en not_active Abandoned
- 2006-05-17 PT PT06779899T patent/PT1912979E/pt unknown
- 2006-05-17 ES ES06779899T patent/ES2367663T3/es active Active
- 2006-05-17 EP EP06779899A patent/EP1912979B1/en not_active Not-in-force
- 2006-05-17 WO PCT/IB2006/002047 patent/WO2006123257A2/en not_active Ceased
- 2006-05-17 CA CA002608324A patent/CA2608324A1/en not_active Abandoned
-
2007
- 2007-11-06 IL IL187187A patent/IL187187A0/en unknown
- 2007-11-28 ZA ZA200710279A patent/ZA200710279B/xx unknown
- 2007-12-17 NO NO20076480A patent/NO20076480L/no not_active Application Discontinuation
-
2011
- 2011-09-22 CY CY20111100921T patent/CY1111859T1/el unknown
-
2012
- 2012-05-24 JP JP2012118718A patent/JP2012184254A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540637A5 (enExample) | ||
| JP2008540636A5 (enExample) | ||
| JP2008540634A5 (enExample) | ||
| JP7299837B2 (ja) | 化合物、組成物、および使用方法 | |
| JP6591532B2 (ja) | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 | |
| JP6503386B2 (ja) | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 | |
| JP6577958B2 (ja) | スピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン誘導体およびＭＤＭ２−ｐ５３阻害剤としてのそれらの使用 | |
| JP2008540635A5 (enExample) | ||
| HUP0301165A2 (hu) | CRF-repector antagonista hatású tetrahidropiridin- és piperidin-heterociklusos-származékok és alkalmazásuk | |
| JP2008539195A (ja) | 新規のオキサジアゾール誘導体及びそれらの医学的使用 | |
| CN109641898A (zh) | 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物 | |
| JP2013539777A5 (enExample) | ||
| EP0861251A1 (en) | Morpholine derivatives and their use as therapeutic agents | |
| JP2005516006A5 (enExample) | ||
| CN1237159A (zh) | 对映导构纯的碱性芳基－环烷基－羟基羧酸酯,其制备方法及其在药品中的应用 | |
| BR122023004130B1 (pt) | Compostos heteroaromáticos, composição farmacêutica e uso dos referidos compostos no tratamento de distúrbios mediados ou associados a dopamina d1 | |
| WO2010132015A1 (en) | New compounds modulating gamma-secretase and their use in the treatment of alpha beta related pathologies, such as alzheimer's disease | |
| CN101622241A (zh) | 苯并咪唑化合物及其医药用途 | |
| JP2017512803A (ja) | ガンマセクレターゼモジュレーターとしてのクロメンおよび１，１ａ，２，７Ｂ−テトラヒドロシクロプロパ［Ｃ］クロメンピリドピラジンジオン | |
| WO2016087487A1 (en) | 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | |
| CN105189497B (zh) | 作为janus激酶抑制剂的n-(2-氰基杂环基)吡唑并吡啶酮 | |
| JP2005537297A (ja) | アルファ−７ｎａｃｈｒ活性を有する１ｈ−ピラゾールおよび１ｈ−ピロール−アザビシクロ化合物 | |
| JP2008511574A (ja) | 精神障害の治療のための縮合三環系誘導体 | |
| EP3788043B1 (en) | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | |
| JP2017519798A (ja) | 芳香族ヘテロ環誘導体及びその医薬的適用 |